AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

An activating BRAF (V600E) kinase mutation occurs in approximately half of melanomas. Recent clinical studies have demonstrated that vemurafenib (PLX4032) and dabrafenib, potent and selective inhibitors of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF), exhibit remarkable activities in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, W, Jin, L, Jiang, C C, Long, G V, Scolyer, R A, Wu, Q, Zhang, X D, Mei, Y, Wu, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847319/
https://www.ncbi.nlm.nih.gov/pubmed/24201813
http://dx.doi.org/10.1038/cddis.2013.441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847319/
https://www.ncbi.nlm.nih.gov/pubmed/24201813
http://dx.doi.org/10.1038/cddis.2013.441

Ejemplares similares